(Press-News.org) Zug, Switzerland and San Diego, CA – Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal of Surgical Oncology.
RESTORE-2 is a 71 patient multi-center, prospective clinical trial using autologous adipose-derived regenerative cell (ADRC)-enriched fat grafting for reconstruction of the breast after cancer surgery. The majority of patients underwent radiation prior to the procedure, creating an unfavorable ischemic environment for which breast reconstruction with ADRC-enriched fat grafting appears to be ideally suited.
Key findings of the trial were:
High rates of investigator (85%) and patient (75%) satisfaction with the overall treatment results at 12 months;
High rates of investigator (87%) and patient (67%) satisfaction with overall breast deformity (based on functional and cosmetic outcomes) at 12 months;
Improved breast contour at both six and 12 months, demonstrated by blinded MRI assessment; and
No local cancer recurrences or serious adverse events related to the ADRC-enriched fat grafting procedure.
"Following cancer treatment, the patient's breast tissue can suffer from radiation injury, scarring and tight skin," said Consultant Plastic and Reconstructive Surgeon Mrs. Eva Weiler-Mithoff, co-principal investigator for RESTORE-2 at the NHS Glasgow Royal Infirmary Hospital. "This new technique is exciting because it may offer the opportunity to resolve some of the most difficult to treat conditions where other approaches, including fat alone, do not achieve satisfactory results."
ADRC-enriched partial mastectomy breast reconstruction is marketed in the EU as the RESTORE Procedure and represents an innovative treatment option with significant cost savings potential. The procedure can be performed on an outpatient basis. Satisfactory results can be achieved in a single procedure for the majority of patients. In contrast, competitive approaches are more costly with lengthy hospital stays, require repeat procedures and increase the overall burden on the healthcare system. Furthermore, because of these limitations, physicians are often reluctant to recommend reconstruction for patients with partial mastectomy defects and radiation-induced damage in the breast.
Each year, approximately 450,000 European women are diagnosed with breast cancer. Of the newly diagnosed breast cancer cases, 70-80% are eligible for breast conserving surgery, where only a portion of the breast is removed rather than the full breast. In the European G5, there are an estimated 1.25 million women who have undergone partial mastectomy. The majority of these patients are left with a sizeable volume defect, scarring and often radiation damage.
"Given that there is no widely accepted reconstructive option available today for partial mastectomy patients, this procedure could well address this substantial unmet need and help complete the overall cancer treatment," said Marc H. Hedrick, president of Cytori.
###
The European Journal of Surgical Oncology is the official journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
About the RESTORE Procedure
During the RESTORE Procedure, fat is taken from the patient's stomach, hips, thighs, or other areas by liposuction. Some of the tissue is processed in Cytori's Celution® system to extract the patient's own regenerative cells which occur naturally inside the tissue. The extracted cells are then combined with the remaining fat tissue, forming an ADRC-enriched fat graft that is injected into the breast to restore its natural look and feel. In addition to providing an entirely natural reconstruction, the procedure is minimally invasive with the potential to reduce scarring. The Celution® system is not commercially available in the United States.
About the RESTORE-2 Trial
RESTORE-2 is a 71 patient European post-marketing trial primarily intended to measure patient and physician satisfaction in reconstructing the breast utilizing the Celution® system. The trial took place at the following sites: Hospital General Universitario Gregorio Marañón in Madrid, Spain, Glasgow Royal Infirmary in Glasgow, Scotland, KU Leuven University Hospitals in Leuven, Belgium, Azienda Ospedaliero Universitaria Careggi in Florence, Italy, Instituto Valenciano Oncología in Valencia, Spain, Norfolk and Norwich University Hospital in Norwich, England, and Jules Bordet Institute of Cancer in Brussels, Belgium.
About Cytori
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow. As a result, we believe these cells can be applied across multiple ischemic conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® system product family. www.cytori.com
Cautionary Statement Regarding Forward-Looking Statements
This press release includes forward-looking statements regarding events, trends and business prospects, which could affect our future operating results and financial position, such as our expectation of increased hospital and patient availability, and our expectation of acceptance of the treatment for lumpectomy and radiation scarring. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include regulatory uncertainties, the perceived quality of our clinical data, physician and patient acceptance of our technology, and other risks and uncertainties described under the "Risk Factors" in Cytori's Securities and Exchange Commission Filings, including its annual report on Form 10-K for the year ended December 31, 2011. Cytori assumes no responsibility to update or revise any forward-looking statements contained in this press release to reflect events, trends or circumstances after the date of this press release.
Cytori breast reconstruction cell therapy trial results published
2012-03-20
ELSE PRESS RELEASES FROM THIS DATE:
Cosmic rays alter chemistry of lunar ice
2012-03-20
DURHAM, N.H. –– Space scientists from the University of New Hampshire and multi-institutional colleagues report they have quantified levels of radiation on the moon's surface from galactic cosmic ray (GCR) bombardment that over time causes chemical changes in water ice and can create complex carbon chains similar to those that help form the foundations of biological structures. In addition, the radiation process causes the lunar soil, or regolith, to darken over time, which is important in understanding the geologic history of the moon.
The scientists present their findings ...
Geologic map of Jupiter's moon Io details an otherworldly volcanic surface
2012-03-20
More than 400 years after Galileo's discovery of Io, the innermost of Jupiter's largest moons, a team of scientists led by Arizona State University (ASU) has produced the first complete global geologic map of the Jovian satellite. The map, published by the U. S. Geological Survey, depicts the characteristics and relative ages of some of the most geologically unique and active volcanoes and lava flows ever documented in the Solar System.
Following its discovery by Galileo in January 1610, Io has been the focus of repeated telescopic and satellite scientific observation. ...
Omega Janitorial Service, With Offices in Houston, Corpus Christi, Dallas and Austin Launch Opening of Second Location in the Houston Area
2012-03-20
With 30 years of management under our belt, Omega Janitorial Service is proud to announce the opening of our second office in the Houston Area. In order to accommodate a growing demand, we have expanded into a brand new facility located off of Beltway 8 North by the International Airport. Our spacious new office and large warehouse offers Omega expanded abilities to receive and house bulk shipments. With increased abilities to house greater amounts of the best products possible, we are continuing to strive to achieve the greatest savings for our customers as our main focus ...
New paper examines poison resistance in snakes around the world
2012-03-20
A new study by University of Notre Dame biologist Michael Pfrender and a team of researchers from the University of Nevada-Reno, Utah State University and the University of Virginia suggests that snakes from different regions of the world have evolved a similar, remarkable resistance to a deadly neurotoxin.
The finding, which appeared in the Proceedings of the National Academy of Sciences, greatly increases scientists' understanding of the genetic basis of adaptation and is a model for understanding the limits to adaptation and the degree to which evolutionary responses ...
Is modern medicine ill with dehumanization?
2012-03-20
"Anyone who has been admitted into a hospital or undergone a procedure, even if cared for in the most appropriate way, can feel as though they were treated like an animal or object," says Harvard University psychologist and physician Omar Sultan Haque. Health care workers enter their professions to help people; research shows that empathic, humane care improves outcomes. Yet dehumanization is endemic. The results can be disastrous: neglect of necessary treatments or prescription of excessive, painful procedures or dangerous drugs.
What are the causes and effects of dehumanization ...
University of Alberta led research may have discovered how memories are encoded in our brains
2012-03-20
University of Alberta led research may have discovered how memories are encoded in our brains.
Scientists understand memory to exist as strengthened synaptic connections among neurons. However components of synaptic membranes are relatively short-lived and frequently re-cycled while memories can last a lifetime. Based on this information, U of A physicist and lead researcher Jack Tuszynski, his graduate student Travis Craddock and University of Arizona professor Stuart Hameroff investigated the molecular mechanism of memory encoding in neurons.
The team looked into structures ...
'Look at me' toddlers eager to collaborate and learn
2012-03-20
Montreal, March 19, 2012 – Parents should think twice before brushing off their child's calls to "look at me!" A Concordia study published in the journal Child Development is the first to show that toddlers' expectations of how their parent will respond to their needs and bids for attention relate to how eager they are to collaborate and learn.
Collaboration in toddlers has been linked to the acquisition of social rules and norms later in childhood.
Understanding what contributes to more collaboration can help improve conscience development in children.
Marie-Pierre ...
Newborn screening for DMD shows promise as an international model
2012-03-20
Investigators at Nationwide Children's Hospital, working with the DNA Sequencing Core Facility at the University of Utah, have developed an approach to newborn screening (NBS) for the life-threatening genetic disorder, Duchenne muscular dystrophy (DMD) and potentially other muscular dystrophies. As a model for NBS, the approach published online in January in the Annals of Neurology provides evidence that this approach could be implemented if approved by regulatory bodies at a state level or alternatively through the Secretary's Advisory Committee on Heritable Disorders ...
Experients may force revision of astrophysical models of the universe
2012-03-20
ALBUQUERQUE, N.M. — In a challenge to current astrophysical models of the universe, researchers at Sandia National Laboratories Z machine and the University of Rostock in Germany have found that current estimates of ice-giant planetary interiors overstate water's compressibility by as much as 30 percent.
The work was reported in the paper "Probing the Interior of the Ice Giants" in the Feb. 27 Physical Review Letters.
"Our results question science's understanding of the internal structure of these planets," said Sandia lead author Marcus Knudson, "and should require ...
Circadian rhythms have profound influence on metabolic output, UCI study reveals
2012-03-20
Irvine, Calif., March 19, 2012 — By analyzing the hundreds of metabolic products present in the liver, researchers with the UC Irvine Center for Epigenetics & Metabolism have discovered that circadian rhythms – our own body clock – greatly control the production of such key building blocks as amino acids, carbohydrates and lipids.
They identified more than 600 liver-originated metabolites, which are the chemical substances created by metabolism that sustain and promote cell health and growth. Approximately 60 percent of these metabolites were found to be dependent on ...